細胞治療市場 - 成長、動向、COVID-19の影響、および予測(2021年~2026年)

Cell Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 115 Pages | 納期: 2~3営業日

価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
細胞治療市場 - 成長、動向、COVID-19の影響、および予測(2021年~2026年)
出版日: 2021年05月13日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 115 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次






第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場の推進力
    • 慢性疾患の有病率の増加
    • 再生医療の採用の増加
    • 細胞治療の開発に関連する臨床研究の数の増加
  • 市場の抑制要因
    • 高い治療費
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • タイプ別
    • 自家移植
    • 同種異系
  • 療法別
    • 間葉系幹細胞療法
    • 線維芽細胞治療
    • 造血幹細胞療法
    • その他の治療法
  • 応用別
    • 筋骨格
    • 悪性腫瘍
    • 心血管
    • 皮膚科および創傷
    • その他の応用
  • 地域
    • 北米
    • 欧州
    • アジア太平洋
    • 中東とアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Anterogen Co., Ltd.
    • Tego Science
    • Chiesi Farmaceutici SpA
    • Corestem Inc.
    • Pharmicell Co Ltd.
    • Fibrocell Technologies Inc
    • Nipro Corporation
    • MEDIPOST Co., Ltd
    • TiGenix(Takeda Pharmaceuticals)
    • Stempeutics Research Pvt. Ltd.
    • Gilead Sciences, Inc.(Kite Pharma, Inc.)
    • Allogene Therapeutics, Inc.
    • Novartis AG
    • Vericel Corporation
    • Organogenesis, Inc.

第7章 市場機会と動向

Product Code: 68691

The Cell Therapy Market is expected to grow with a CAGR of 6.8% over the forecast period.

The impact of the COVID-19 pandemic on the cell therapy market is expected to be significant as most of the companies have been focusing on the development of cell-based therapies for COVID-19 treatment. For instance, in April 2020, Calidi Biotherapeutics, Inc., revealed that the Investigational New Drug (IND) application submitted by its partner, Personalized Stem Cells, Inc. (PSC), has received FDA approval for the treatment of COVID-19 and pneumonia patients using stem cell therapy. The impact of COVID-19 is also expected to show a positive impact on the studied market as most of the pharmaceutical, biotechnology, and research institutes have been focusing on the development of cell therapy-based treatment against COVID-19. For instance, in November 2020, Novartis obtained the license for the Mesoblast's cell therapy remestemcel-L for the treatment of COVID-19. Thus, owing to the rising research activities pertaining to the development of cell therapies in treating SARS-CoV2 infection, the studied market is expected to impact during the COVID-19 pandemic era.

The cell therapy market is anticipated to witness healthy growth due to the increasing prevalence of chronic conditions, rising adoption of regenerative medicine, and rise in the number of clinical studies about the development of cellular therapies.

Chronic diseases and conditions are on the rise worldwide. According to the Global Alliance for Chronic Diseases (GACD) 2018, one in ten individuals is predicted to have type 2 diabetes by 2035 worldwide and is predicted to be the 7th leading cause of death by 2030. Also, according to Globocan 2020, the new cancer cases that were diagnosed accounted for 19,292,789 in 2020 worldwide, with 9,958,133 deaths due to cancers globally. Among all cancers, breast cancer accounted for 2,261, 419 new cancer cases, followed by lung (2,206,771), Prostate (1,414,259) and colon (1,148,515) new cases in 2020.Additionally, as per the International Diabetes Federation Diabetes Altas Ninth Edition 2019, nearly 463 million population globally are living with diabetes worldwide and are expected to reach 700 million by 2045. Therefore the increasing prevalence of chronic conditions, along with the government assistance and numerous companies investing heavily in stem cell therapy research and development is predicted to help to stimulate industry growth. The proven effectiveness of cell therapy products coupled with increasingly favorable guidelines on cell therapy research and manufacturing also aids in the positive impact of the studied market over the forecast period.

Key Market Trends

Allogeneic Therapies Segment is Expected to Account for the Largest Share in the Cell Therapy Market

Allogeneic therapies rely on a single source of cells to treat many patients. They increase the risk of eliciting an immune response within a patient, and immunosuppressive therapies are sometimes administered in combination with allogeneic products. Therefore the increasing inclination of physicians towards therapeutic use of allogeneic therapies coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas are some of the major factors driving the growth. Allogenic cells have benefits as they produce their own immune stem cells, that kill the cancer cells that remain even after high-dose treatment with cytotoxic drugs. This response is called a graft-versus-cancer effect and this is used in the prevention or treatment of cancer relapse. The aforementioned factors are expected to drive the market over the forecast period.

Moreover, cancer recurrence is a foremost concern of patients and their caregivers. Fear of recurrence can negatively affect the quality of life, and as per the "cancer recurrence statistics" published in 2018, approximately 7% of patients develop severe and disabling fear that includes constant intrusive thoughts and misinterpretation of mild and unrelated symptoms. These recurrences are usually observed in children and patients suffering from breast and oropharyngeal cancer. Allogenic transplantation is recommended for patients with a high risk of relapse after successive courses of induction chemotherapy. Thus, an increase in the incidence of cancer relapse has provided growth avenues to the demand for allogeneic therapies. Furthermore, the rising number of clinical trials which are required to gain regulatory approval for new medications to advance patient care is expected to boost the segment growth. For instance, ALLO-501, ALLO-501A, ALLO-715, UCART19, and UCART19 by Allogene is providing growth opportunities to the segmental growth. Thus, owing to the rising number of research on allogenic therapy for cancer, and associated benefits, the studied segment is anticipated to register steady growth over the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

North America is estimated to retain the largest share of the Cell Therapy market due to the presence of a strong regulatory framework to promote cellular therapy development, the existence of industry key players, and also the presence of leading universities that supports the research activities in the United States. Also, the factors attributing to the high growth of the studied market in the region include the increasing prevalence of chronic conditions, rising adoption of regenerative medicine, and rise in the number of clinical studies about the development of cellular therapies.

There is a tremendous amount of funding in the United States available, to increase Research and Development activities in the field of cancer. As per the data published by the National Cancer Institute (NCI), in 2019, the Department of Defense and Labor, the Department of Health and Human Services, and the Education Appropriations Act allotted USD 5.74 billion to the NCI, which indicated a USD 79 million increase over FY 2018. As cell therapies have huge potential in treating cancer, the availability of funding is expected to further help in overall market growth. In July 2020, US FDA approved Tecartus (brexucabtagene autoleucel) which is a cell-based gene therapy for the treatment of mantle cell lymphoma (MCL). Also, in July 2020, FDA has approved Talaris Therapeutics, Inc., an investigational new drug application for the evaluation of Talaris' novel cell therapy FCR001 in the treatment of diffuse systemic sclerosis (SSC). Moreover, as per the Regulatory Affairs Professionals Society, in 2019 USFDA has granted 34 designations associated with regenerative medicine advanced therapy wherein 68 out of 100 are cell therapy products. The rising adoption of regenerative medicines and related clinical studies in the region is thus anticipated to propel the market growth over the forecast period.

Competitive Landscape

The Cell therapy market is moderately competitive and has a presence of a considerable number of companies. The major companies of the studied market are Pharmicell Co., Ltd., Corestem, Inc., Chiesi Farmaceutici S.p.A., Tegoscience, Anterogen Co., Ltd., TiGenix (Takeda Pharmaceuticals), Stempeutics Research Pvt. Ltd., Nipro Corporation, Medipost Co., Ltd among others. These companies are evolving through various strategies such as investment in research and development, acquisitions, partnerships, and collaboration to secure the market position. For instance, in Jan 2020, Allogene Therapeutics, Inc. and SpringWorks Therapeutics, Inc announced a clinical trial collaboration agreement for the evaluation of ALLO-715 along with Nirogacestat in Multiple Myeloma patients.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Chronic Conditions
    • 4.2.2 Rising Adoption of Regenerative Medicine
    • 4.2.3 Rise in Number of Clinical Studies Pertaining to the Development of Cellular Therapies
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Therapies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Type
    • 5.1.1 Autologous
    • 5.1.2 Allogeneic
  • 5.2 By Therapy
    • 5.2.1 Mesenchymal Stem Cell Therapy
    • 5.2.2 Fibroblast Cell Therapy
    • 5.2.3 Hematopoietic Stem Cell Therapy
    • 5.2.4 Other Therapies
  • 5.3 By Application
    • 5.3.1 Musculoskeletal
    • 5.3.2 Malignancies
    • 5.3.3 Cardiovascular
    • 5.3.4 Dermatology & Wounds
    • 5.3.5 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Anterogen Co., Ltd.
    • 6.1.2 Tego Science
    • 6.1.3 Chiesi Farmaceutici S.p.A.
    • 6.1.4 Corestem Inc.
    • 6.1.5 Pharmicell Co Ltd.
    • 6.1.6 Fibrocell Technologies Inc
    • 6.1.7 Nipro Corporation
    • 6.1.8 MEDIPOST Co., Ltd
    • 6.1.9 TiGenix (Takeda Pharmaceuticals)
    • 6.1.10 Stempeutics Research Pvt. Ltd.
    • 6.1.11 Gilead Sciences, Inc. (Kite Pharma, Inc.)
    • 6.1.12 Allogene Therapeutics, Inc.
    • 6.1.13 Novartis AG
    • 6.1.14 Vericel Corporation
    • 6.1.15 Organogenesis, Inc.